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Epstein-Barr virus (EBV) attachment to primary B
cells initiates virus entry. Although CD21 is the only
known receptor for EBVgp350/220, a recent report
documents EBV-infected B cells from a patient
genetically deficient in CD21. On normal resting B
cells, CD21 forms two membrane complexes: one
with CD19 and another with CD35. Whereas the
CD21/CD19 complex is widely retained on immortal-
ized and B cell tumor lines, the related complement-
regulatory protein CD35 is lost. To determine the
role(s) of CD35 in initial infection, we transduced
a CD21-negative pre-B cell and myeloid leukemia
line with CD35, CD21, or both. Cells expressing
CD35 alone bound gp350/220 and became latently
infected when the fusion receptor HLA II was coex-
pressed. Temporal, biophysical, and structural
characteristics of CD35-mediated infection were
distinct from CD21. Identification of CD35 as an
EBV receptor uncovers a salient role in primary infec-
tion, addresses unsettled questions of virus tropism,
and underscores the importance of EBVgp350/220
for vaccine development.
INTRODUCTION
Epstein-Barr virus (EBV) is the first virus found to be causally
associated with human malignancy (Epstein et al., 1965). Like
all herpesviruses, EBV persists lifelong through support of a
complex life cycle consisting of alternate lytic and latent phases,
each family member sequestered in a distinct cellular niche.
EBV latency is maintained in the B cell compartment (Miyashita
et al., 1997). To date, CD21 is the only known B cell receptor
for EBV (Fingeroth et al., 1984; Frade et al., 1985; Nemerow
et al., 1985; Tanner et al., 1987). Tethering of EBV to the B cell
membrane initiates efficient entry and is mediated by a high-
affinity (108 M) interaction between envelope glycoprotein (gp)
350/220 and CD21 (Tanner et al., 1988). Unique among herpes-
viruses, gp350/220 dominates the outer membrane of EBV and
is the major target of neutralization (Edson and Thorley-Lawson,
1981; Sashihara et al., 2009). Proximity to the B cell surfaceCpromotes interaction between a second envelope protein,
gp42, in complexwith gHgL and the virus coreceptor HLA II, acti-
vating fusion that in concert with other EBV proteins (Connolly
et al., 2011; Hutt-Fletcher, 2007), delivers nucleocapsid to the
cytoplasm. Whether initial contact with surface receptors influ-
ences the outcome of infection is unknown.
In vivo, latent infection typically begins with EBV entry into
naive tonsillar B cells. In vitro, the normal resting B cell is most
efficiently infected and immortalized to form lymphoblastoid
cell lines (LCLs). EBV also infects oral epithelial cells, though
the pathways of infection and physiologic outcome, lytic infec-
tion, are distinct. As a tumor virus, EBV is primarily associated
with a spectrum of B lymphoid and nasopharyngeal epithelial
malignancies (Rickinson and Kieff, 2007), reflecting tropism of
EBV for these cells. Although most EBV+ tumors of hematopoi-
etic lineage originate from B and some T cells (activated T cells
can express CD21 and HLA II), sporadic identification of EBV
in blood cells not known to express CD21 as well as reports of
gp350/220-induced signaling in CD21-negative cells (e.g., pre-
B, monocyte, dendritic, NK cells, and activated neutrophils)
(Busse et al., 2010; Calattini et al., 2010; Larochelle et al.,
1998) have long proved puzzling. Importantly, the recent finding
that B cells from a patient with genetic deletion of CD21 can be
readily immortalized with EBV indicates that even on B cells, an
alternate attachment receptor must exist (Thiel et al., 2012).
Human CD21, consistently detected on B cells and FDCs, is
the receptor for C3d (complement [C0] receptor type 2, CR2),
for CD23 (low-affinity IgE receptor), and binds interferon a (Aso-
kan et al., 2006). An ectodomain (ED) of 15–16 short consensus
repeat (SCR) modules is followed by a hydrophobic transmem-
brane (TM) and short cytoplasmic tail (CT) (Moore et al., 1987).
All CD21 ligands bind within two flexible N-terminal SCRs (Prota
et al., 2002). CD21’s role(s) is best understood in the context of
humoral immunity, though much investigation was conducted
in mice. A related though clearly diverged murine protein
(mCD21/CD35) serves the dual function of both a C3d and
a C3b/C4b receptor (C0 receptor type 1, CR1)/CD35 based on
alternative splicing of the ED (Roozendaal and Carroll, 2007).
Studies mainly provide insight into the roles of CD21 because
the CT of human CD21 is most similar to that of mCD21/CD35
(Fingeroth, 1990). On quiescent B cells, CD21 associates nonco-
valently with other proteins forming two mutually exclusive
membrane complexes along with free CD21. The CD21/CD19/
CD81 complex is conserved in mouse, retained on human Bell Reports 3, 371–385, February 21, 2013 ª2013 The Authors 371
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Figure 1. Stable Expression of Recombinant CD35 and CD21 in Nalm6 Pre-B Cells and K562 Myeloid Cells with or without HLA II
(A) Top view shows FC. Nalm6 cells lack CD21 and CD35 but express HLA II, CD19, and CD81 as shown using specific anti-human mAbs CD35, CD21, HLA II,
CD19, and CD81 (black lines). Isotype controls are filled. x axis, log fluorescence intensity; y axis, relative cell number. Middle view presents IB. Neither CD21 nor
CD35 was visualized in Nalm6 or Nalm6 neo (control) cells, though evident in the respective transfectants (Nalm6CD35, CD21). Raji and B958 (B cell lines) control
for CD21 expression, and human splenic monocytes/macrophages control for CD35 expression. Actin served as loading control. Bottom view shows IFA. CD35
(green) and CD21 (red) were visualized at the surface of the respective Nalm6 transfectants. Nuclei were stained blue (DAPI).
(B) Top view shows FC. K562 lacks CD21 and CD35. However, after transfection and selection, CD35, CD21, and coexpressed CD21/CD35were detected (black
lines) using mAbs. Isotype controls are filled. Although K562 lacks HLA II, when CIITA was transfected, HLA II was expressed at the cell surface (denoted K562+)
(legend continued on next page)
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cell tumor lines, and has been extensively characterized,
whereas the distinct complex between CD21 and CD35 is lost
(Tuveson et al., 1991).
Human CD35 is an independent membrane gp best studied as
an immune adherence and phagocyte receptor. A regulator of C0
activity (RCA) gene family member, CD35 also consists of a long
ED, standard TM, and short CT. The common F allele contains 30
SCRs organized into four long homologous repeats (LHRs), A–D
of 7 SCRs each, followed by SCRs 29–30 adjacent to the plasma
membrane. Although highly expressed on B cells and FDCs,
CD35 is also present on RBCs, neutrophils, monocyte/macro-
phage, dendritic, subpopulations of T cells, and renal podocytes.
Depending on cell type, CD35 may bind, transport, and/or
phagocytose particles or immune complexes (ICs) tethered by
activated C0 proteins C3b, iC3b, C4b, C1q, and mannan-binding
lectin (Klickstein et al., 1988; Krych-Goldberg and Atkinson,
2001). Multiple SCRs from distinct LHRs may be utilized for the
different interactions. Unlike CD21, but analogous to most
RCA proteins, CD35 provides cofactor activity for Factor I modu-
lating the C0 cascade to protect cells frommembrane attack, and
cleavage of C3b by CD35 generates C3d that may in turn bind
nearby CD21 (Krych-Goldberg and Atkinson, 2001). RBC CD35
is also a pathogen receptor that binds Plasmodium falciparum
merozoites via adhesin PfRH4, rosettes infected RBC via
PfEMP1 (Spadafora et al., 2010) and indirectly tethers HIV and
other infectious agents.
Notably, though consistently identified on primary B cells,
CD35 expression is minimal or undetectable on B-LCLs and
most tumor lines (Schlossman et al., 1995). Thus, knowledge
of its role in B cell biology is more limited. On normal B cells
(tonsillar), nearly all CD35 associates with CD21 (Tuveson
et al., 1991), though each receptor can cap independently (Tso-
kos et al., 1988). Although crosslinking CD21 to mIgM enhances
Ca2+ flux, promotes tyrosine phosphorylation of intracellular
targets, and augments B cell proliferation, crosslinking of
CD35 stimulates terminal B cell differentiation (Weiss et al.,
1987) and is antiproliferative (Erdei et al., 2009), underscoring
the complexity of signals integrated when B cells engage ICs
bearing diverse C0 fragments.
Herein, we show that CD35 is itself an attachment receptor for
EBV. Infection of cells expressing CD35 alone was unaltered by
monoclonal antibodies (mAbs) that directly block infection
through CD21. Although CD35 is sufficient for EBV binding,
HLA II coexpression is additionally required for entry and latent
infection. The dominant virion ligand gp350/220 binds CD35
because mAb 72A1 directed to a glycan-free region that
interacts with CD21 inhibits CD35-mediated infection as well.
Yet, structural, biophysical, and temporal characteristics ofas shown by FC in the bottom row. Middle view presents IB. Expression patterns
CD35, HLA II+), K562+CD35 (CD21, CD35+, HLAII+), K562+CD21 (CD21+, CD35
IB. Raji and splenic mono/macrophages served as controls. Bottom view displ
microscopy. CD35 (green), CD21 (red), and colocalized receptors (yellow) are s
a single K562 cell. Three-dimensional acquisition followed by deconvolution and re
colocalized with CD35, whereas 57.02% of CD35 molecules colocalized with CD
(C) PCR. Reverse transcription of cellular RNA followed by quantitative PCRwas p
undetectable in Nalm6, Nalm6neo, Nalm6 CD35, K562, K562+, and K562+ CD
reference plasmid pCI-puroCD21. GAPDH cDNA (control) was generated under
Table S1 cites the origin of cell line X50-7.
CCD35-based infection are distinct. Finally, we provide evidence
that EBV downregulates CD35 upon B cell infection, likely
contributing to delayed recognition of its role. Identification of
CD35 as an attachment receptor reconciles unsolved observa-
tions about how EBV signals to and infects CD21-negative
hematopoietic lineage cells, including immature B cells, and
provides a broad understanding of viral pathogenesis with impli-
cations for cancer biology, autoimmune disease, and vaccine
development.
RESULTS
Nalm6/Pre-B and K562/Myeloid Cell Lines Lacking
CD21 and CD35 Support Stable Expression
after Gene Transfer
To analyze whether CD35 contributes to EBV infection, we
developed a panel of informative cell lines that display different
combinations of key surface proteins associated with CD21 on
primary B cells (Figures 1A and 1B). Antigen expression was
documented by flow cytometry (FC), immunoblot (IB), and immu-
nofluorescence analysis (IFA). We chose two background hema-
topoietic lineages, lymphoid and myeloid, because EBV+ tumors
from the latter have been reported (Larochelle et al., 1998),
though normal precursors lack CD21. Whereas B cell lines rarely
express CD35, most express CD21 except certain pre-B cell
lines such as Nalm6 (Table S1). Nalm6 expresses a pre-B cell
receptor, CD19, and HLA II that arise earlier in ontogeny than
CD35 or CD21 (Tedder et al., 1997). K562, an immature myeloid
line, lacks a B cell receptor, CD19, HLA II, CD21, and CD35 (Fig-
ure 1B) but is readily transduced with different components of
the EBV entry pathway. Both lines express CD81, a tetraspan
that can also complex with CD19/CD21. No CD21 expression
was detected in lone CD35 or HLA II transfectants by IB (Figures
1A and 1B) and confirmed by PCR (Figure 1C). Cell line panels
Nalm6, Nalm6neo, Nalm6puro, Nalm6 CD35, and Nalm6
CD21, and K562, K562neo, K562puro, K562-HLA II (denoted
K562+), K562+CD35, K562+CD21, and K562+CD21/CD35 were
used for further investigation. Ab sources for all experiments
are listed in Table S2.
CD35 Binds EBV
As a prelude to infection experiments, we sought to document
EBV-bound CD21 expressed on Nalm6 and K562 cells and
that binding was specific. Cells were incubated with EBV and
washed, and attachment was detected with 2L10, a mAb
directed to a gp350/220 epitope distant from the CD21 contact
site (Tanner et al., 1988). To our surprise, EBV also bound to cells
expressing CD35 on both Nalm6 and K562 transfectants, thoughdisplayed left to right in K562 parent (CD21, CD35, HLA II), K562+ (CD21,
, HLA II+), and K562+CD21/CD35 (CD21+, CD35+, HLA II+) were confirmed by
ays IFA. Receptor expression in dual K562 transfectants is demonstrated by
hown. Nuclei are stained blue (DAPI). Sequential views of CD35 and CD21 in
constitution showed that in this representative cell, 73.62%of CD21molecules
21.
erformed using described primers (Experimental Procedures). CD21 cDNAwas
35 but present in Nalm6 CD21, K562+ CD21, X50-7 (control, Table S1), and
identical conditions.
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Figure 2. EBV Binds CD35 Expressed on Nalm6 and K562+
(A) EBV indirectly detected with mAb 2L10 anti-gp350/220 and GAM FITC binds CD21, and also CD35+ Nalm6 cells, but not Nalm6 or Nalm6neo controls.
(B) Identical results were obtained when EBV was incubated with K562+ clones and analyzed as described. K562+CD21, +CD35, and +CD21/35 bind EBV,
whereas K562+ does not.
(C) Polyclonal anti-CD35 partially blocks binding of CD35+, but not CD21+ K562+ cells (middle row). Polyclonal anti-CD21 does not prevent binding of CD35+ cells,
though it blocks CD21+ cells (top row, control). Polyclonal anti-CD19 (irrelevant control) does not alter any EBV-receptor interaction (bottom row).
(legend continued on next page)
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neither parental nor vector control lines bound virus (Figures 2A
and 2B). Because there was no evidence of cross-contamination
(Figure 1), and neither 2L10 nor secondary Ab bound nonspecif-
ically to Nalm6, K562, or transfected sublines (data not shown),
we investigated the specificity of binding. Multiple sources of
EBV including standard B958, variants EBfaV-GFP and B958-
Tet-BZLF1, and Akata virus all bound CD35-expressing cells,
supporting specific interaction (data not shown). Although
none of several mAbs (2B11, YZ1, E11, 543, 3D9) that recognize
distinct epitopes on CD35 (Chen et al., 2007) blocked EBV
binding to CD35+ cells, even upon addition of a 2 Ab or when
pooled (data not shown), a rabbit polyclonal IgG directed to
CD35 partially inhibited attachment (Figure 2C), whereas poly-
clonal anti-CD21 did not. Based on cell culture and experimental
systems employed (absence of relevant C0 factors, heat inactiva-
tion of serum, washing of cells before EBV incubation, use of
purified EBV), it seemed unlikely that C0 activation occurred
generating C3b on the virus envelope for interaction with
CD35. Still, to rule out this possibility, we preincubated EBV
with polyclonal anti-C3, which did not alter EBV binding as
shown for K562+CD35 (Figure 2D). Moreover, EBV colocalized
with CD35 at the surface of K562 CD35 (no HLA II) and Nalm6
CD35 cells (Figure 2E). Thus, EBV directly binds CD35, an inter-
action independent of virus-associated C3b and CD21.
CD35 Mediates EBV Infection in the Presence of HLA II
Next, we queried whether CD35 also mediates infection, or
whether EBV might be irreversibly tethered to the cell surface
by CD35 (a rigid protein), or be phagocytosed and destroyed.
Nalm6 CD35, Nalm6 CD21, Nalm6, and control lines were incu-
bated with EBfaV-GFP (a variant B958 strain that expresses
EGFP from the viral genome after infection) and analyzed by
microscopy at 18, 36, 72, and 96 hr postinfection. By 72 hr,
Nalm6 CD21, Raji (CD21+ CD35, EBV+ Burkitt lymphoma [BL]
line susceptible to EBV ‘‘superinfection’’), and also Nalm6
CD35 became infected with EBfaV-GFP, as shown by fluores-
cence (Figure 3A). The time course of infection via CD21
compared with CD35 was distinct: fluorescent cells first ap-
peared at 18 hr in Nalm6 CD21 but were not visible until
36 hr after Nalm6 CD35 was incubated with EBV (data not
shown). Although the relative receptor density of CD35 and
CD21 may have varied in some assays, delayed fluorescence
of CD35-expressing cells was consistent in multiple experi-
ments. Sorting EGFP-expressing cells enabled establishment
of stable lines that grew well and were further evaluated after
6months (Figure 3B).We reliably detected EBV latentmembrane
protein 1 (LMP1) in these cells by IB (Figure 3C), whether they
originated fromNalm6 CD21 or CD35 lines, documenting persis-
tent infection. Interestingly, whereas CD21 expression was re-
tained in infected Nalm6 CD21 cells, CD35 expression could
not be detected after stable infection of Nalm6 CD35 lines, an
observation we will return to (Figure 3C, bottom).(D) Polyclonal anti-C3 preincubated with EBV also does not alter any EBV-recep
(E) EBV colocalizes with CD35. Top view shows that EBV (titer nonsaturating) (gree
CD35 (HLA II+) cells. Nuclei are stained blue (Hoechst). Top view also shows adjac
presents colocalization of EBV with CD35 at the plasma membrane of a single
overlapping channels (Experimental Procedures). Bottom view shows that EBV c
CDespite EBV binding, neither K562 CD21 nor CD35 expressed
EGFP after incubation (data not shown). K562, unlike Nalm6,
lacks HLA II, the lymphocyte coreceptor and only known cellular
ligand for the EBV fusion protein gp42 extensively reviewed in
Hutt-Fletcher (2007) and Shaw et al. (2010). To assess whether
HLA II could also serve as a coreceptor for CD35-expressing
cells, dual transfectants were generated as previously reported
using transcription factor CIITA (LeibundGut-Landmann et al.,
2004) to upregulate HLA II (Li et al., 1997) (Figure 1B). Although
neither K562 nor K562+ was susceptible to infection, K562+
CD21 (control), K562+CD35, and K562+CD21/CD35 were all
readily infected as shown by visualization of EGFP (Figure 3D).
Moreover, preincubation of EBV with mAb F-2-1 directed to
gp42, but not with an isotype control Ab, blocked infection of
HLA II+ Nalm6 CD35 cells (Figure 3E).
EBV Contacts CD35-Expressing Cells through
gp350/220
gp350/220 is the most highly expressed protein on the EBV
envelope. The prior observation that specific Abs to gp350/220
entirely blocked EBV absorption to the normal B cell membrane
(Tanner et al., 1987) suggested that EBVgp350/220 might
mediate attachment to CD35 aswell. Mutant analyses and struc-
tural studies showed that N-terminal gp350/220 was the major
site of CD21 interaction (SCR1-linker-SCR2), and contacts
were mapped (Kovacs et al., 2010). However, the ED of gp350/
220 is long (863 amino acids) and highly N and O glycosylated;
thus, ample potential epitopes for further interaction with
CD35 (perhaps other ligands) remained. mAb 72A1 binds the
N-terminal domain of gp350/220, directly blocking absorption
by CD21, whereas mAb 2L10 binds a C-terminal region (Tanner
et al., 1988) that has no effect on attachment. Preincubation with
72A1 prevented EBV infection of Nalm6 CD35, K562+CD35, and
K562+CD21/35 (Figure 4), though neither 2L10 nor 2L10 with
secondary Ab was inhibitory. These results not only confirmed
prior reports that 72A1 was potently neutralizing but, impor-
tantly, revealed that N-terminal gp350/220 was also utilized for
CD35 attachment, thereby suggesting that the docking site
was near, possibly the same as that used for interaction with
CD21, or that a major conformational change produced upon
72A1 binding, perhaps mimicking CD21, compromised subse-
quent CD35 interaction.
Temperature and Structure Distinguish CD35-EBV
Interaction
Virus infection-blocking experiments are classically performed
on ice to prevent capping, internalization, and/or shedding of
ligand-receptor pairs and probes. Nalm6 CD21 cells avidly
bound EBV when incubated on ice or at 37C in the presence
of azide (data not shown). However, binding of EBV to Nalm6
CD35 was at least 10-fold more avid at 37C than on ice (Fig-
ure 5A, top row). Nevertheless, a series of comparative infectiontor interaction.
n) colocalizes with CD35 (red) on the surface of K562CD35 (HLA II) and Nalm6
ent K562 CD35 cells that are joined by binding of aggregated EBV. Middle view
cell that is indicated (arrows) and graphically displayed by pixel analysis in
olocalizes with CD35 on Nalm6 CD35 cells.
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Figure 3. EBV Infects CD35+ Cells that Express the Fusion Receptor HLA II
(A) Seventy-two hours after incubation of Nalm6 CD21 or CD35 with EBfaV-GFP, fluorescent cells were detected by microscopy. No fluorescence was detected
in identically incubated vector control or parent Nalm6 cells. When Raji (CD21+, HLA II+, EBV+ BL line) was superinfected with EBfaV-GFP, fluorescence was also
detected (control).
(B) EGFP-expressing Nalm6 CD35 and CD21 cells enriched by sorting maintained stable fluorescence after 6 months in culture.
(C) IB of stable Nalm6 CD35 and Nalm6 CD21 confirmed LMP1 expression in both lines. Nalm6 CD21 retained long-term receptor expression after EBV infection,
whereas Nalm6 CD35 did not.
(legend continued on next page)
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inhibition assays was carried out on ice. When Nalm6 CD35 (Fig-
ure 5A) was compared to Nalm6 CD21 (Figure 5B), it was evident
that mAb 72A1, but not 2L10 anti-gp350/220 (control), blocked
EBV infection of both C0 receptor-expressing Nalm6 cells
(Figures 5A and 5B, third row). mAb OKB7, which recognizes
the gp350/220 attachment site on CD21, only prevented infec-
tion of Nalm6 CD21 (Figure 5B, second row), whereas polyclonal
C3 Ab had no effect on EBV infection of either line (Figures 5A
and 5B, third row). Polyclonal anti-CD35 IgG partially inhibited
infection of Nalm6 CD35 but did not alter Nalm6 CD21 infection
(Figures 5A and 5B, second row). Soluble recombinant CD35
(full-length ED), while decreasing Nalm6 CD35 infection, in three
experiments appeared to enhance infection of Nalm6 CD21
cells, raising the possibility of interaction in trans between
soluble recombinant CD35 and cell surface CD21. These find-
ings demonstrate that CD35, as well as CD21, can engage
EBV on the cell surface and mediate infection in the presence
of HLA II. However, temperature requirements for EBV absorp-
tion, tempo of initial infection, and domain structure of ligand-
receptor binding (see below) all differ.
EBV Contacts Multiple LHRs and SCRs 29–30
at the Plasma Membrane
The highly repetitive structure of the SCRs comprising each LHR
has yielded complex patterns of ligand binding based on subtle
differences in affinity. For example, LHR A preferentially binds
C4b, whereas both LHR B and LHR C preferentially bind C3b
and likely iC3b. LHR D binds C1q and mannan-binding lectin
(Ghiran et al., 2000; Krych-Goldberg and Atkinson, 2001).
Recently, P. falciparum PfRh4 was shown to bind CD35 with
high affinity within three N-terminal SCRs (Tham et al., 2011).
To begin to more precisely decipher the structural basis for
EBV-CD35 interaction at the plasmamembrane, we constructed
five truncation mutants consisting of one LHR (A–D) or SCRs
29–30 fused to the CD35 TM-CT (Figure 6A). All mutants were
expressed at the surface of K562+ cells as detected by FC and
confirmed by IB (Figures 6B and 6C). Membrane-adjacent
SCRs 29–30 were readily detected by FC but poorly detected
after denaturation by IB. EBV binding was promiscuous, similar
to reports for certain C0 fragments. EBV bound each of the
LHR mutants as well as mutant SCRs 29–30 (Figure 6D).
However, all mutants bound less well than full-length CD35.
Somewhat unexpectedly, despite attachment, infection was
absent based on lack of fluorescence in HLA II+ cells expressing
CD35 mutants (data not shown) compared to full-length
controls. These results indicate that EBV binds CD35 differently
than CD21 because contact withmultiple LHRs is more similar to
that of certain C0 ligands.
EBV Downmodulates CD35
Loss of CD35 after stable infection of Nalm6 CD35 in contrast to
CD21 upregulation prompted reinspection of their expression(D) K562 cells that expressed CD21, CD35, or both became fluorescent (suscept
cells that expressed HLA II alone.
(E)When EBVwas preincubated with mAb F-2-1 to gp42, infection of Nalm6CD35
UPC10 had no effect comparable to cells infected with EBV in the absence of an
The source of F-2-1 mAb is described in Table S2.
Cpatterns on different B cells. CD21 upregulation is unusual
because viral-binding proteins are typically downmodulated
after infection. A multilaboratory blinded evaluation of CD35
mAbs (Schlossman et al., 1995) confirmed consistent CD35
expression on fetal and adult B cells, whereas no recorded B
cell lines (BJAB [EBV], Daudi [EBV+], IM9 [EBV+], JY [EBV+],
Nalm6 [EBV], Raji [EBV+], U266 [EBV]) expressed CD35. In
contrast, all lines (except Nalm6, pre-B) expressed CD21.
Although several groups previously reported increased or stable
CD21 expression on superinfected BL lines (Calender et al.,
1990; Wang et al., 1990), a single account (using polyclonal
Ab) described upregulation of CD35 (Cohen et al., 1987). BL41,
an EBV BL, is frequently used to model ‘‘physiologic’’ EBV
infection (Rickinson and Kieff, 2007) because its surface pheno-
type resembles that of a normal B cell. Upon infection with strain
B958, a stable type III latent (immortalizing) infection is estab-
lished, similar to LCLs. Two sources (BB, FW) of BL41 expressed
CD21 and variably CD35. However, after superinfection, CD21
was upregulated, whereas CD35 was lost (Figure 7A; Table
S1). EBNA-2, a transcription factor expressed in latency III,
was previously shown to upregulate CD21 (Calender et al.,
1990; Wang et al., 1990). Using a series of BJAB sublines,
a gift of FredWang, we assessedwhether EBNA-2 also regulates
CD35 (CD21 and CD35 are low but detectable in some BJAB
clones each expressing a single EBV latent protein). Although
CD21 expression uniformly increased in clones expressing
EBNA-2, CD35 became undetectable (Figure 7B). There was
no change in CD21 or CD35 expression in clones expressing
vector (pZ-3, pZ-4), EBNA-1, or LMP1. In EBNA-3C-expressing
clones, CD21 upregulation was as described by Wang et al.
(1990), but results for CD35 were equivocal.
Normal human B cells are short lived in culture unless immor-
talized. Upon isolation, B cells express both CD21 and CD35.
However, after outgrowth of oligo or monoclonal LCLs, no or
minimal CD35 is detected by FC (unpublished data; Table S1).
In contrast, CD21 is consistently upregulated, though to varying
degrees. Our results support published literature indicating that
most B cell tumor lines (EBV or EBV+) express no or low CD35
and suggest that EBV infection of normal B cells and superinfec-
tion of most CD21+ B cell lines downmodulate CD35. Although
EBNA-2 may mediate repression of CD35 as well as upregulate
CD21, the background of the tumor line in which EBNA-2 is
expressed may also be relevant (Cordier-Bussat et al., 1993).
DISCUSSION
The B cell tropism of EBV was established shortly after its
discovery in 1964, and a high-affinity B cell receptor, CD21,
was identified 2 decades later. Still, unresolved questions about
how EBV contacts, signals, variably enters, and at times persists
in certain CD21 hematopoietic cells (some pre-B, plasmablast,
monocyte/macrophage, dendritic, activated neutrophil, and NKible to EBV infection) when the fusion receptor HLA II was coexpressed, unlike
(HLA II+) was abolished, whereas preincubation of EBVwith the isotype control
y Ab. Nalm6 cells lacking CD35 but that express HLA II+ were not infected.
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Figure 4. mAb 72A1, Directed to N-Terminal
gp350/220, Blocks Infection of CD35-Ex-
pressing Nalm6 and K562+ Lines
Top view shows that Nalm6 CD21, CD35, and Raji
(control) are susceptible to EBV infection, whereas
Nalm6 is not, as shown by EGFP visualization at
72 hr. Preincubation of EBV with anti-gp350/220
(mAb 72A1) blocks infection of CD21 and/or CD35+
cells. Bottom view presents infection of all K562+
receptor-bearing lines that is likewise blocked when
EBV is preincubated with mAb 72A1. The source of
72A1 mAb is described in Table S2.cells) remain. On review, virtually all implicated cells regularly or
sporadically expressed CD35, lending credence to the idea that
this structurally related protein might substitute for CD21. The
recent demonstration that B cells from a patient with genetic
deletion of CD21 (compound heterozygote) are immortalized
by EBV provides clear evidence that an alternate receptor exists.378 Cell Reports 3, 371–385, February 21, 2013 ª2013 The AuthorsHerein, we demonstrate that CD35 medi-
ates EBV attachment to the cell surface
and supports entry into a CD21-pre-B
and myeloid cell line when the fusion
receptor HLA II is coexpressed. Whether
CD35 plays the key role in establishing or
alters the course or pattern of primary B
cell infection is under review.
Significantly, although CD35 like CD21
bound gp350/220, and absorption was
blocked by an identical mAb (72A1), each
EBV-C0 receptor interaction was unique.
CD35 binding was not restricted to
N-terminal SCRs (a feature of several path-
ogen-RCA protein interactions). Rather,
EBV bound each LHR as well as SCRs
29–30, a feature analogous to certain C0-
type contacts and that may explain why
individual CD35 mAbs were ineffective in
preventing attachment. CD35 is adjacent
to CD21 on the RCA locus chromosome
1q32, and evidence supports development
of CD35 as an independent type 1 TM
protein by homologous recombination
late in primate evolution (Birmingham and
Hebert, 2001). Indeed, a study of homology
relationships among all known RCA and
other SCR-containing proteins showed
that CD21 SCRs 1–2 were most similar to
SCRs 3–4 (LHR A), 10–11(LHR B), 17–18
(LHR C), 24–25 (LHR D), and 29–30 of
CD35 (Krushkal et al., 2000), signifying
that gp350/220 may contact related
SCRs. Unlike full-length CD35, none of
the truncation mutants conferred infectivity
implying (among other scenarios) that
multiple contacts were needed to retain
EBV on CD35 during membrane transit,a longer span or a flexible spacer domain(s) was required for
delivery to the fusion receptor, or signaling was modified.
EBV infection of CD35+ cells was highly sensitive to tempera-
ture. An approximate 10-fold decrease in infection was observed
when cells were infected on ice versus 37C. Such variance
often occurs in warm-blooded animals and typically reflects
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Figure 5. Temperature and Structure
Distinguish CD35 from CD21-Mediated
Infection
Cells were infected with EBfaV-GFP in the ab-
sence or presence of a competing ligand. Exper-
iments were performed on ice unless otherwise
noted.
(A) Top row shows that infection of CD35+ cells
is >10-fold more efficient when virus is introduced,
washed, and incubated at 37C, compared with
initial incubation and wash on ice. Second row
shows that preincubation of Nalm6 CD35 with
OKB7 anti-CD21 does not block virus infection, nor
does polyclonal anti-CD35, though addition of 2
Ab confers modest inhibition. Third row shows that
preincubation of EBV with mAb 72A1 blocks infec-
tion of CD35+ lines, whereasmAb 2L10 and anti-C3
have no effect. Fourth row shows that pre-
incubation of EBV with soluble recombinant CD35
blocks most infection of CD35+ cells, whereas
soluble recombinant forms of CD21 are ineffective.
(B) Top row displays infection of CD21+ cells on
ice. Second row shows that preincubation with
OKB7 entirely blocks EBV infection, whereas
polyclonal anti-CD35 even with 2 Ab has no
effect. Third row shows that preincubation of EBV
with mAb 72A1 blocks infection of CD21+ lines,
whereas mAb 2L10 and anti-C3 have no effect.
Fourth row shows that preincubation of EBV with
soluble recombinant CD21 SCRs 1–2, but not
soluble recombinant CD35, blocks EBV infection
of CD21+ cells. One representative of three
experiments is displayed.
The sources of all antibodies are described in
Table S2.thermodynamic effects (Haywood, 1994) on affinity or avidity
(e.g., bond formation or dissolution), movement in the plasma
membrane (e.g., capping versus patching—a notable character-
istic distinguishing EBV entry into normal B cells from cell lines;
Nemerow and Cooper, 1984), and/or rate of internalization of
ligand-receptor complexes (Holland and McLaren, 1959). One
or all noted properties may differentiate CD35-EBV interactions.
Time to infection (at 37C) scored by initial visualization of EGFP
EBV was consistently slower (18 hr delay) in CD35 compared
with CD21 or coexpressing cells, suggesting that the respective
receptor-EBV complexes may form distinct cytoskeletal associ-
ations and/or deliver independent intracellular signals that sepa-Cell Reports 3, 371–385,rately impact the competence of recipient
cells to support infection. On resting B
cells, where both receptors are ex-
pressed and associate, signals may be
integrated in ways that ultimately reveal
how differences in transformation effi-
ciency of individual B cells arise, a
phenomenon not well understood.
What Does CD35-Mediated
Infection Imply for EBV Biology?
Among the barriers to the study of EBV
biology is the inherent diversity of theprimary human B cell. Human B cells require isolation from
mixed specimens, cannot be cultured long term, and short-
term culture changes their behavior. They are extremely difficult
to transfect, and lentivirus infection alters gene expression. Even
B-LCLs are suboptimal for many studies due to high biological
noise and in vitro artifacts (Choy et al., 2008). This, coupled
with absence of a robust animal model (both EBV infection and
CD35 as a type 1 TM protein are restricted to humans), has
impeded decisive work. Experiments of nature that uncover
and resolve important biological questions are often most infor-
mative. For example, discovery of EBV-lymphoproliferative
disease upon introduction of T cell-suppressive transplantFebruary 21, 2013 ª2013 The Authors 379
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Figure 6. CD35 Truncation Mutants: Surface Expression and EBV Binding
(A) Schematic representation of CD35, and truncationmutants (LHRs A–D, SCRs 29–30). Five individual cDNAmutants were constructed ligated to the TMandCT
of parental CD35 and incorporated into the vector pCIneo. The relative position of mutant fragments (LHRs A–D, SCRs 29–30) and flanking restriction enzyme
sites are indicated.
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B Figure 7. Comparative Expression of CD35
and CD21 on EBV and EBV+-Converted
BL Lines by FC
(A) BL41 (EBV) from two sources (BB top, FW
bottom) upregulates CD21 but downregulates
CD35 after stable EBV (B958) infection. Regard-
less of source and clonality, CD21 was up-, and
CD35 downmodulated. As predicted CD23 ex-
pression increased upon superinfection (control).
(B) Analysis of BJAB (EBV) clones that express
individual EBV latent cycle proteins (EBNA-2,
EBNA-1, EBNA3C, LMP1) or vector controls (pZ3,
pZ4, pGPT) confirmed that EBNA-2 upregulates
CD21 and suggested that CD35 loss was also
EBNA-2 dependent. Assays were repeated a
minimum of three times. x axis, log fluorescence
intensity, three log display; y axis, cell number
(50,000 events).
Cell lines are described in Table S1.therapy and discovery of SAP mutation in Duncan’s syndrome
each provided essential evidence that EBV infection was regu-
lated by the cellular immune system (Rickinson and Kieff,
2007). Likewise, the observation that patients with agammaglob-
ulinemia with no or immature (typically CD35, CD21) B cells
are not infected by EBV (even in the epithelial compartment) re-
vealed an essential role of B cells in initiation of primary infection
(Faulkner et al., 1999). Because CD35 arises earlier than CD21 in
B cell ontogeny (Tedder et al., 1997), virtually all naive B cells
express both. Thus, the recent finding that B cells from a patient
lacking CD21 (compound heterozygote) can be readily immortal-(B) Each mutant was independently transfected into K562+ cells and surface expression documented by FC u
of coreceptor HLA II is displayed because no mutant-bearing cells became infected.
(C) IB confirmed that each mutant was of the predicted MW. Controls (K562, K562+, K562+CD35, monocyte
(D) EBV bound each mutant as shown by FC, but in no case was binding equal to that of full-length CD35. S
Cell Reports 3, 371–385,ized with EBV in vitro and serological
evidence of infection highlights the exis-
tence of an alternative EBV receptor. To
date, genetic absence of CD35 has not
been reported.
Is CD35 a Physiologically Relevant
EBV Receptor?
Several lines of evidence suggest that
CD35 is a physiologically relevant EBV
receptor on normal human B cells. For
example, human pro- and early pre-B
cells that express only CD35 (precedes
CD21 in B ontogeny) can be infected
and immortalized (Ernberg et al., 1987).
Although transfection of CD21 and HLA
II may mediate restricted (latency I or II)
infection of a spectrum of transformed
cell lines, including mouse B lymphoma
cells, neither primary murine B cells ex-
pressing CD21 and HLA II nor murine
stem cells electroporated with EBV anddifferentiated into B cells can be immortalized and expanded
in vitro (Zychlinska et al., 2008). Because CD35 in the form of
a type 1 TM protein first appears late in primate evolution, it is
unclear if expression in mouse B cells will be informative.
Although superinfection of human CD21+ cell lines results in
restricted latency, infection of primary B cells (and certain model
lines such as BL41 that are CD21+ and CD35+) yields latency III.
When primary B cells are mitogen activated, CD21 is upregu-
lated, CD35 downregulated, and susceptibility to immortaliza-
tion rapidly decreases (Einhorn and Klein, 1981; Roome and
Reading, 1987). Furthermore, the observation that CD35 butsing polyclonal anti-CD35. Concurrent expression
s) were as expected.
ee also Figure 1B.
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not CD21 is downregulated after EBV infection replicates
behavior of other major virus-binding and entry proteins that
thereby avoid superinfection and inhibition of virus release.
When mature tonsillar B cells are first exposed to salivary EBV,
CD35 andCD21 are closely associated and interact through their
ED (Tuveson et al., 1991) and possibly other domains. Thus, it is
most likely that they work in concert to optimize primary infection
and establish a latent state.
EBV, CD35, Lupus, Cancer—and Malaria?
The current results also raise provocative new questions relevant
to EBV-associated disease. For example, patients with active
lupus (often females of African heritage) have high rates of
EBV+ B cells in their blood (Gross et al., 2005), and CD35 expres-
sion on memory B cells is depressed (Isaa´k et al., 2008). Does
EBV enforce CD35 downregulation, and does it contribute to
ongoing polyclonal B cell activation and lupus flares, particularly
among children in whom EBV seroprevalence is high (James
et al., 1997)? Does the sustained B cell activation predispose
to lymphoproliferative disease? CD35 on RBCs is a receptor
for P. falciparum, a driving force in human evolution. Does EBV
modulate RBC CD35—in lupus, in malaria? Might ongoing EBV
production, whereas potentially predisposing to lupus and
lymphoma (rare outcomes), paradoxically afford protection
from severe malaria?
gp350/220 as a Vaccine
The observation that CD35 contacts an identical EBV ligand
coupled with a slower tempo of infection, distinct protein inter-
actions, and temperature dependence in addition to frequent
absence of CD35 on B cell lines likely confounded interpreta-
tion of past experiments. Our results establish that both
CD21 and CD35 can mediate EBV attachment and support
entry when a fusion coreceptor is present (Nalm6 CD35) or
introduced (K562+CD35). Because CD35 also binds gp350/
220, reports attributing signaling to gp350/220 contact with
CD21 alone on normal B cells or to innate immune receptors
in other leukocytes may need to be reexamined in light of
possible CD35 interaction. Identification of this additional
gp350/220 receptor further suggests that vaccination might
protect from a wider spectrum of disease than is currently
appreciated because some of the rare EBV+ tumors and auto-
immune phenomena not well explained by a CD21-mediated
path might result from CD35-mediated entry in a relevant
microenvironment.
Significantly, unlike most herpesviruses, gp350/220 alone
dominates the EBV envelope. Certain Abs to gp350/220 com-
pletely neutralize in vitro EBV infection, gp350/220 is a target
of antibody-dependent cell-mediated cytotoxicity (ADCC), and
maternal serum with a high content of gp350/220 Ab is protec-
tive. Small vaccine trials of soluble recombinant gp350/220
have shown partial efficacy (Sashihara et al., 2009). Demonstra-
tion that gp350/220 binds CD35 as well as CD21 highlights the
potential of gp350/220 as an immunogen, particularly if delivered
in an innovative vehicle free of viral nucleic acid to mucosal sites
that robustly harness humoral and cellular immune responses—
a vaccine poised to prevent infection, cancer, and autoimmune
disease.382 Cell Reports 3, 371–385, February 21, 2013 ª2013 The AuthorsEXPERIMENTAL PROCEDURES
Cell Lines
Nalm6, EBV+/ BL lines, EBV+ LCLs, EBV producer lines Akata, Akata-GFP,
B958, EBfaV-GFP, Tet-BZLF1 and B958, and the myeloid leukemia line
K562 were obtained and cultured as detailed in Extended Experimental Proce-
dures. Monocyte/macrophages were isolated as described (Fingeroth et al.,
1989) from discarded de-identified spleens consented for research and
approved by both New England Organ Bank and BIDMC institutional review
boards.
Plasmids
Full-length CD35 and CD21 cDNAs were cloned into pCIneo (Promega) and
pCIpuro, respectively. pCIpuro was constructed from pCIneo and pPUR
(Clontech) backbones as detailed in Extended Experimental Procedures.
Plasmid containing CIITA (pZeoCIITA) was a gift of Dr. Jeremy Boss (Riley
et al., 1995). Truncated forms of CD35 ED encoding LHR A, LHR B, LHR C,
LHR D, and SCRs 29–30 were synthesized in vitro (GENEWIZ) based on the
genomic sequence of CD35 (GenBank NM_000573.3) and cloned into pCIneo
(Figure 6).
Transfection/Selection
Plasmids containing relevant cDNAs were transfected into parental Nalm6
and K562 cells using Lipofectamine (Life Technologies) according to the
manufacturer’s directions. After 48 hr, cells were selected in media containing
the indicated antibiotic (Life Technologies): Zeocin (CIITA), puromycin (CD21),
and Geneticin (CD35, truncation mutants).
Antibodies
Abs used for all experiments are listed in Table S2.
Cytometric Analysis and Sorting
Single-cell suspensions were prepared in PBS containing 2% doubly heat-
inactivated FCS. Abs used for staining are listed in Table S2. FC was per-
formed on a FACScan or LRSII benchtop FC (Becton Dickinson, BD), and
data were analyzed using CellQuest Pro Version 4.0.1 (BD) and/or FlowJo
Cytometry Analysis software (Tree Star). A minimum of 10,000 events was
recorded for each analysis. Sorting of antibiotic-selected cells was performed
on a FACSAria (BD Biosciences).
Imaging of C0 Receptors
Cells were stained with specific mAbs for 30 min on ice. Nuclei were stained
with DAPI 33342 (Sigma-Aldrich) for 5 min at room temperature (RT). Stained
cells were washed, mounted (Mounting Medium; DakoCytomation), and
imaged using an UPlanApo 603 1.42 NA objective on an Olympus BX62
microscope fitted with a cooled Hamamatsu Orca AG CCD camera. The
microscope, filters, and camera were controlled as outlined (Ghiran et al.,
2008). Deconvolution is detailed in Extended Experimental Procedures.
Colocalization of EBV and CD35
Cells were fixed in 4% formaldehyde for 10 min at RT, washed 23 in buffer
containing 0.5% IgG-free BSA, and incubated with Alexa Fluor 594 Zenon-
labeled anti-CD35 rabbit polyclonal Ab and Alexa Fluor 488-labeled mouse
anti-EBV IgG for 20 min at RT, washed 23 in the presence of 0.03% Hoechst
33342, mounted on slides using Fluoromount (DakoCytomation), and visual-
izedwith a UplanApo 603 1.42 objective fitted on anOlympus BX62motorized
microscope. Images were recorded with a Qimaging Emc2 cooled CCD
camera controlled by Slidebook v.5.0 (Intelligent Imaging Innovations, 3i).
For colocalization studies, the microscope was fitted with Zero-Shift DAPI,
Texas red, and GFP-green filters (Semrock) providing exact registration
between pixels upon channel overlap.
Imaging of EGFP-EBV
EGFP-EBV-expressing cells were imaged using filters set for FITC with an
excitation wavelength of 488 nm resulting in emission at 507 nm as described
by Speck and Longnecker (1999).
IB
IBs were performed by standard methods (Extended Experimental Proce-
dures) using nonreducing Laemmli SDS-PAGE sample buffer (Boston Bio-
Products). Protein was visualized with an ECL kit (GE Healthcare Life
Sciences), and images were obtained using a LAS-4000 luminescent image
analyzer (Fujifilm).
PCR
Cellular RNA was extracted with a RNeasy Total RNA kit (QIAGEN), treated
with DNase (Promega), repurified on RNeasy spin columns, and reverse
transcribed with the RNA to cDNA EcoDry Premix (Oligo dT) kit (Clontech)
using an iCycler thermal cycler (Bio-Rad). PCR amplification of cDNA was
performed using High Yield PCR EcoDry Premix (Clontech) with specific
primers spanning the CT of CD21: sense 50-GTGCCAATCGGATCACC-30
and antisense 50-TCCGCTGAATTCCAAGC-30. Control GAPDH primers were
sense 50-GAGTCAACGGATTGTGTCGT-30, antisense 50-TTGATTTTGGAGG
GATCTCG-30. Amplification conditions were 95C for 5 min for denaturation,
35 cycles at 95C for 1min, 55C for 2min, and 72C for 2min using an iCycler.
Virus Production
B958 cells harboring Tet-BZLF1 or EBfaV-GFP were induced to release EBV
into the supernatant as respectively described by Kudoh et al. (2003) and
Speck and Longnecker (1999). Supernatants were passed through a
0.45 mmcellulose acetate filter and centrifuged at 10,000 rpm (SLA-1500 rotor,
Sorvall RC-5B Centrifuge; DuPont) for 90 min. Concentrated pellets were
diluted 1:50 with RPMI, aliquoted, and stored at 80C until use. Other EBV
strains were prepared as described (Fingeroth et al., 1984).
Virus Binding and Infection Assays
Cells (1 3 106) seeded in triplicate were incubated with standard amounts of
EBV under different conditions, as detailed in Extended Experimental Proce-
dures. EBV binding was assessed by FC, infection by microscopic visualiza-
tion of EGFP EBV in cells, and detection of LMP1 by IB (Extended Experimental
Procedures).
SUPPLEMENTAL INFORMATION
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